New drug combo targets Hard-to-Treat cancers
NCT ID NCT07477743
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called HC010 combined with chemotherapy in people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. About 331 participants will join, and researchers will also look at whether the tumors shrink or stop growing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells be trained to fight advanced GI cancers?
- Genetic blueprint of tumors may guide smarter cancer treatment
- Triple-Drug cocktail aims to tackle Hard-to-Treat cancers
- New writing therapy aims to ease fear in advanced cancer patients
- New hope for advanced cancer patients? early trial of ZE94-0605 begins
- App helps cancer patients track symptoms and improve care